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Abstract 20	  
Precision medicine continues to be the benchmark to which we strive in cancer research. Seeking 21	  
out actionable aberrations that can be selectively targeted by drug compounds promises to 22	  
optimize treatment efficacy and minimize toxicity. Utilizing these different targeted agents in 23	  
combination or in sequence may further delay resistance to treatments and prolong antitumor 24	  
responses. Remarkable progress in the field of immunotherapy adds another layer of complexity 25	  
to the management of cancer patients. Corresponding advances in companion biomarker 26	  
development, novel methods of serial tumor assessments and innovative trial designs act 27	  
synergistically to further precision medicine. Ongoing hurdles such as clonal evolution, intra and 28	  
intertumor heterogeneity and varied mechanisms of drug resistance continue to be challenges to 29	  
overcome. Large-scale data-sharing and collaborative networks using next generation sequencing 30	  
platforms promise to take us further into the cancer ‘ome than ever before, with the goal of 31	  
achieving successful precision medicine. 32	  
  33	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The Precision Medicine Rationale 34	  
Oncology research has evolved in parallel with improved understanding of the cancer genotype 35	  
and phenotype ushering in a new age of precision medicine (see Glossary for this and all terms 36	  
in bold). This is colloquially termed “the right drug, for the right patient, at the right time”. These 37	  
biological therapies target specific abnormalities within the cancer cell genome, proteome, 38	  
immunome and/or “any-ome” that are involved in cancer initiation, development, and survival 39	  
[1,2]. In stark contrast to the historic “one-size-fits-all” chemotherapy approach, precision 40	  
medicine combines individual patient characteristics with their tumor genomic landscape to 41	  
enable matching with molecularly targeted agents and immunotherapeutics to maximize 42	  
treatment efficacy and minimize toxicity.  43	  
 44	  
As insights into the genomic and immunomic complexity of cancer increase with the aid of next 45	  
generation sequencing (NGS) and other sophisticated platforms, daunting challenges continue 46	  
to hinder the promise of precision medicine to find the “right drug”. These include clonal 47	  
evolution encompassing tumor cell aberrations that alter and accumulate over time and tumor 48	  
heterogeneity reflecting (epi)genetic differences between tumors (intertumor heterogeneity) 49	  
and indeed within the same tumor specimen (intratumor heterogeneity). Additionally, 50	  
logistical hurdles, such as small and underpowered molecular-specific cohorts, biostatistical 51	  
obstacles and the need for innovative trial designs to incorporate modern translational studies 52	  
further impede progress [3]. Alongside our improved identification of the “right patient” and the 53	  
“right time”, there has been a tenacious attempt to find surrogate biomarkers of disease 54	  
response and modern noninvasive methods of serial tumor monitoring. The emergence of 55	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immuno-oncology and its rapid integration into standard of care treatment for several different 56	  
tumor types has added another level of complexity to personalized medicine [4 – 6].  57	  
 58	  
In an effort to accelerate progress, the USA recently launched the Precision Medicine Initiative 59	  
and with it, a million-patient, multimillion-dollar longitudinal cohort study. The future of 60	  
personalized oncology is bright, but solving the challenges that hamper its progression is a slow 61	  
endeavor, often fraught with disappointment. This review sets out to address the challenges and 62	  
barriers to achieving universal precision medicine in oncology, and conceivable solutions to 63	  
overcome them. We focus on the challenges in interpreting genomic and epigenomic 64	  
abnormalities, discuss how such aberrations change through clonal evolution and how this gives 65	  
rise to intratumor and intertumor heterogeneity. We discuss the promise, pitfalls and 66	  
opportunities surrounding the use of NGS, surrogate markers of disease response, theranostics, 67	  
and novel clinical trial designs. 68	  
 69	  
Deciphering aberrations within the cancer cell 70	  
While the turn of the century has seen an exponential growth in the collection of cancer “omics” 71	  
data (genomics, interactomics, transcriptomics, proteomics and metabolomics), it remains a 72	  
struggle to differentiate “passenger” aberrations that do not impact cell function from significant 73	  
“driver” abnormalities to which the cancer cell is addicted for growth and survival [7]. Single 74	  
tumor biopsies can often underestimate the number of driver events in part due to intratumor 75	  
heterogeneity and intertumor variations, potentially leading to sample bias. Furthermore, 76	  
aberrant events that are more frequent within the tumor are easier to isolate and may give the 77	  
illusion of clonal dominance, whereas low frequency driver aberrations can often be missed or 78	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overlooked. To date, there has been some success in prohibiting tumor growth when pursuing 79	  
actionable aberrations, including imatinib (Gleevec®, Novartis) for the treatment of chronic 80	  
myelogenous leukemia and gastrointestinal stromal tumors, gefitinib (Iressa®, AstraZeneca) for 81	  
epidermal growth factor receptor (EGFR)-mutant lung cancer, and crizotinib (Xalkori®, Pfizer) 82	  
for anaplastic lymphoma kinase (ALK)-positive lung cancer, to name a few.  83	  
 84	  
Clonal somatic aberrations found within all cancer cells have been acquired early in 85	  
tumorigenesis [8]. The tumor genomic landscape further evolves over time as demonstrated by 86	  
the Darwinian successive acquisition of beneficial aberrations, resulting in superior “fitter” 87	  
clones that eventually surpass their parent clones [9, 10]. Branched evolution results in multiple 88	  
distinct subclones due to the deterministic outgrowth of superior and better-adapted cell groups. 89	  
These can develop as a result of direct exposure to cancer therapies (selection pressure) 90	  
resulting in treatment resistance [11 – 14]. Certain tumors express increased genomic instability 91	  
such as melanomas, tobacco-exposed lung cancers or cancers with DNA repair defects including 92	  
microsatellite instability are predisposed to developing excessive subclonal aberrations [13]. 93	  
Figure 1 represents an example of clonal evolution with resultant inter and intratumor 94	  
heterogeniety. 95	  
 96	  
Although treatments aimed at clonal driver aberrations can result in tumor responses, 97	  
highlighting the importance of identifying these early events, subclonal abnormalities may also 98	  
need to be targeted to avoid or delay the emergence of resistance to therapies [15]. McGranahan 99	  
and colleagues have shown that although mutations in known driver genes occurred early in 100	  
cancer evolution, later subclonal actionable aberrations were also identified [16]. These included 101	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BRAF (V600E), IDH1 (R132H), PIK3CA (E545K), EGFR (L858R), and KRAS (G12D) 102	  
aberrations, which may ultimately hinder the efficacy of molecularly targeted agents. Over 20% 103	  
of IDH1 mutations in glioblastomas and approximately 15% of PI3K-AKT pathway aberrations 104	  
across all tumors were subclonal. RAS-MAPK pathway aberrations are less likely to be 105	  
subclonal than PI3K-AKT network gene abnormalities. There is also context dependency 106	  
between tumors, for example, loss of the tumor suppressor gene PTEN is a clonal driver event in 107	  
triple negative breast cancer, but often subclonal in prostate tumors [17, 18].  108	  
 109	  
Clonal evolution can give rise to intertumor and intratumor heterogeneity when selection 110	  
pressures from the host’s immune system, peritumoral microenvironment and/or anticancer 111	  
therapy result in vastly divergent molecular landscapes between the primary tumor and 112	  
associated metastases as well as variances within a single tumor specimen itself [14,19]. A 113	  
greater understanding of this respective inter and intratumor heterogeneity provides plausible 114	  
reasons for the observation of differential treatment responses at different disease sites and novel 115	  
mechanisms of resistance [20]. It has also led to concerns about conventional methods of 116	  
(epi)genomic analysis using archival tissue, which may not truly be reflective of the current state 117	  
of disease after multiple lines of anticancer therapies. Additionally, a single specimen from one 118	  
biopsy site may potentially mislead the physician’s choice of treatment due to intratumor 119	  
heterogeneity [21], as pictorially represented in Figure 2. Several large trial-based efforts are 120	  
ongoing to advance our understanding of inter and intratumor heterogeneity, such as TRACERx 121	  
in non-small cell lung cancer [NCT01888601] and BEAUTY in breast cancer [NCT02022202]. 122	  
 123	  
	   7	  
The functional validation of each genomic aberration is important and may be achieved through 124	  
different approaches, including the analysis of relevant cell lines, in vivo mouse “avatars” such 125	  
as patient-derived xenografts, genetically engineered mouse models (GEMMs) or organoid 126	  
cultures (miniature 3-dimensional tissue forms) [22, 23]. Additional genomic databases and 127	  
libraries such as the Catalogue of Somatic Mutations In Cancer (COSMIC) compile somatic 128	  
aberrations along with their functional relevance and are useful publicly available sources of data 129	  
[24]. Stratifying the functional importance of identified aberrations takes into account predicted 130	  
bioinformatic algorithms and preclinical data to allow ranking of these aberrations into levels or 131	  
tiers, as eloquently detailed by Van Allen and colleagues [25]. Tier 1 refers to a molecular 132	  
alteration that has been robustly validated in early phase or Phase III clinical trials, Tier 2 defines 133	  
the aberration as being identified as significant in single and/or underpowered Phase I/II trials, 134	  
Tier 3 aberrations have potential functional impact suggested by preclinical studies and finally, 135	  
Tier 4 aberrations are predicted to have significance but without supporting clinical or preclinical 136	  
data. 137	  
 138	  
Next generation sequencing, liquid biopsies and theranostic biomarkers panels 139	  
Expanding the breadth of precision medicine requires further progress in a number of key areas. 140	  
Among these, we discuss the utility of NGS and associated obstacles, as well as the development 141	  
of liquid biopsies and theranostics for use in the clinic. High-throughput NGS methods for 142	  
detecting cancer gene aberrations comprise ‘OMIC technologies, such as the sequencing 143	  
platforms of DNA Seq, RNA Seq, CHIP Seq and Methyl Seq. They involve whole genome 144	  
sequencing (WGS) and whole exome sequencing (WES). WES focuses upon the coding 145	  
regions of the genome, whereas WGS is a comprehensive assessment involving all nucleotides of 146	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an individual’s DNA, but it is often limited by its increased, albeit improving, fiscal burden, 147	  
enormity of data returned and slow turnaround time [26]. To date, large-scale collaborative and 148	  
pioneering ‘OMIC databases such as the International Cancer Genome Consortium 149	  
(http://www.icgc.org/) [27], Cancer Genome Atlas (http://cancergenome.nih.gov/) and Cancer 150	  
Cell Line Encyclopedia [28] have identified several hundred cancer-driver mutations and varied 151	  
genomic aberrations across multiple cancer types, often uncovering potential targetable 152	  
abnormalities [8, 29, 30].  153	  
 154	  
Similar to DNA interrogation, technologies applied to RNA sequencing have advanced our 155	  
understanding of the transcriptome and allowed the identification of important microRNAs and 156	  
non-coding RNAs [31]. RNA Seq has been additionally useful in detecting oncogenic fusion 157	  
proteins such as EML4-ALK in non-small cell lung cancer (NSCLC) [32, 33], differentially 158	  
expressed transcripts between tissues and the discovery of single nucleotide variations. It has 159	  
been also successful in elucidating the tissue-of-origin in patients with carcinomas of unknown 160	  
primary [34]. Beyond NGS and RNA Seq, further decoding of the functions and interactions of 161	  
highly dynamic and closely linked cancer proteins has led to a whole science of proteomics, 162	  
metabolomics and interactomics [35]. Finally, as well as genetic abnormalities, epigenetic 163	  
changes such as post-translational histone modification and DNA hypermethylation are also 164	  
likely to be functionally important in the development and progression of cancer [36 – 38]. These 165	  
are subject to intensive research and have led to the development of epigenetic agents. 166	  
 167	  
Serial ‘OMIC assessments allow for a dynamic interaction with the tumor as it potentially 168	  
changes over time. Longitudinal metachronous assessments from sequential tumor biopsies or 169	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other biomarkers allow repeated analysis to decipher the tumor status during treatment and upon 170	  
progression to assess for differences [39, 40]. This vantage point allows strategic alterations in 171	  
therapy, uncovers novel mechanisms of acquired drug resistance and aids in the interpretation of 172	  
underlying mechanisms of clonal evolution, metastasis and cancer differentiation.  173	  
 174	  
Despite the great potential of NGS, the data that emerge from such analyses are ultimately only 175	  
as good as the source tissue. Inter and intratumor heterogeneity may result in molecular 176	  
characteristics of analyzed archival tumor biopsies that do not accurately represent the current 177	  
tumor (epi)genome. There is also often further uncertainty over the preservation techniques of 178	  
formalin and paraffin that can damage DNA integrity. The most obvious solution involves 179	  
multiple, fresh serial tumor biopsies from different parts of the primary cancer itself, as well as 180	  
many secondary metastases to minimize sampling bias and to paint a comprehensive molecular 181	  
canvas of the tumor’s genomic landscape. Such biopsies are however invasive, costly, 182	  
logistically challenging, and importantly may potentially result in harm to patients. Better 183	  
strategies of obtaining fresh contemporary tissue for NGS analysis to enable rational matching 184	  
with targeted therapies, monitoring of treatment response and the detection of emerging resistant 185	  
subclones are thus essential.  186	  
 187	  
An alternative strategy to the use of multiple successive tumor biopsies is the utility of “liquid 188	  
biopsies” which appear to be a promising and viable alternative. Circulating tumor cells (CTCs) 189	  
are sloughed from primary and metastatic tumor cells into the bloodstream, which can then be 190	  
isolated and analyzed by NGS technology [41]. Comparative genomic analyses of CTCs, 191	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primary tumors and metastatic deposits in colorectal and prostate cancer have expressed 192	  
concordance, supporting their potential application as an adjunct to tumor analysis [42 – 44].  193	  
 194	  
Circulating cell-free DNA (cfDNA) are derived from cancer cells following apoptosis and/or 195	  
necrosis and harbor genetic alterations reflective of the parent cell [45]. These can also be 196	  
isolated and sequenced to identify mutational changes in “real-time” prior to radiological disease 197	  
progression with high sensitivity [46 – 48]. cfDNA are often detected in the absence of CTCs 198	  
[49] and can be detected in other bodily fluids such as urine and saliva, with high concordance 199	  
reported [50, 51]. The EGFR T790M mutation was detected in serum and urine cfDNA, despite 200	  
being unidentified in the tumor biopsy potentially due to intratumor heterogeneity or perhaps 201	  
inferior sampling [52]. Furthermore in the Phase I/II TIGER-X study (NCT01526928), the 202	  
antitumor response to the EGFR mutation-specific inhibitor rociletinib (Clovis Oncology) was 203	  
comparable regardless of which NSCLC patient tissue the T790M mutation was identified in. 204	  
The Phase I AURA study of the EGFR mutation-specific inhibitor osimertinib (AZD9291, 205	  
AstraZeneca) in EGFR T790M mutant NSCLC utilized serial cfDNA assessments to reveal 206	  
distinct molecular subtypes emerging, including the gain of another resistant EGFR mutation 207	  
C797S and development of alternative resistance mechanisms [53].  208	  
 209	  
The use of liquid biopsies continues to strive to overcome current challenges and limitations. 210	  
cfDNA is currently only applicable in tumors where the exact driver mutation is already known, 211	  
such as EGFR. The use of next generation sequencing when applied to cfDNA is in an early 212	  
stage of development with promising results reporting identification of tumor mutations in 213	  
almost 70% of patients [48]. cfDNA analyses may also be limited by the tumor tissue to normal 214	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tissue cfDNA ratio [54]. Standardization and optimization of bioinformatics analyses and 215	  
validated software programmes are essential to ensure cross-study comparisons going forward. 216	  
 217	  
Prospective precision medicine studies currently underway propose to explore surrogate 218	  
biomarkers, intra and intertumor heterogeneity, as well as clonal and subclonal evolution in 219	  
response to different treatments via tumor samples, CTC enumeration and cfDNA analysis to 220	  
devise novel individualized and adaptive management strategies and are listed in Table 1. 221	  
 222	  
Another major challenge to precision medicine is the dearth of predictive biomarker panels for 223	  
use in conjunction with molecularly targeted agents and other therapies to guide the rational 224	  
matching of patients with antitumor therapeutics. Where possible, it is therefore essential to 225	  
advance the development of both drug and predictive biomarker in parallel. This field of 226	  
theranostics – using diagnostic testing to rationally select targeted therapies – relies on biomarker 227	  
assays being analytically validated and appropriately clinically qualified. The BRAF inhibitor, 228	  
vemurafenib (Zelboraf®, Genentech) was developed and approved with its companion 229	  
diagnostic PCR assay (Cobas 4800®, Roche) following clinical validation in a Phase III trial (55, 230	  
56]. Similar theranostic development scenarios were observed with the ALK inhibitor crizotinib 231	  
(Xalkori®, Pfizer) and its ALK break-apart probe for fluorescence in situ hybridization (FISH) 232	  
[57], imatinib (Gleevec®, Novartis) and BCR/ABL-positive chronic myeloid leukemia [58], and 233	  
trastuzumab (Herceptin®, Genentech) in ERBB2-positive breast cancers [59]. Figure 3 shows 234	  
different treatment approaches for the molecularly targeted agents often using companion 235	  
predictive biomarkers to improve patient outcomes. 236	  
 237	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Designing early phase precision medicine trials 238	  
The current drug development process is lengthy, ineffective and costly. In early phase trials, 239	  
disappointingly, less than 10% of drugs are successfully approved for eventual use in the general 240	  
cancer population [2,60]. There is thus renewed impetus to alter the design of clinical trials to 241	  
evolve with the demands of precision medicine. Here we discuss novel trial designs, innovative 242	  
targeting strategies and the need for new yardsticks of response.  243	  
 244	  
Historically, Phase I trials have focused on conventional safety and tolerability endpoints to 245	  
determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) by enrolling 246	  
patients with advanced cancers using a classical 3+3 dose escalation trial design. Such a trial 247	  
strategy, which was originally designed for cytotoxic chemotherapies, is painstakingly slow and 248	  
may result in large proportions of patients treated at subtherapeutic dose levels. Compared to 249	  
chemotherapies, novel molecularly targeted agents may also be well tolerated without DLTs 250	  
observed during the first cycle of therapy. As many targeted therapies are oral drugs taken on a 251	  
regular basis until disease progression, in contrast to chemotherapies given over a limited 252	  
number of cycles, the former are often associated with intolerable low-grade chronic toxicities 253	  
that restrict their long-term use [2, 61]. Such findings are often only detected in late Phase III 254	  
registration trials, requiring dose modifications and interruptions of the Phase I MTD [62]. 255	  
 256	  
There are a number of novel strategies to improve the current drug development paradigm [63]. 257	  
Phase I patient populations now often include mutation-focused expansions where possible. For 258	  
example, basket trials assess single or a family of genomic abnormalities using NGS and other 259	  
platforms for treatment with matched targeted therapies, regardless of tumor origin (Table 1). 260	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Alternatively, umbrella trials assess a number of pre-specified genetic aberrations with matched 261	  
targeted agents, usually involving specific tumor types (Table 1). Novel precision medicine 262	  
clinical trial designs include accelerated titration design and model-based designs using continual 263	  
reassessment methods, which allow the exploration of a greater number of dose levels and more 264	  
patients to be treated at active therapeutic levels [64 – 66]. 265	  
 266	  
An essential aspect of patient care is the ability to track tumor biology through the treatment 267	  
journey. We propose the following biomarker-driven strategies to evade resistance mechanisms 268	  
and prolong antitumor treatment responses: (1) switch approaches, (2) combination regimens, 269	  
and (3) priming/herding strategies. These are illustrated in Figure 3. 270	  
 271	  
Biopsy-driven treatment as in Figure 3A alters targeted therapies according to multiple tumor 272	  
biopsy analysis results. Switch strategies use real-time NGS analysis of tissue or liquid biopsy 273	  
samples to detect early signs of drug resistance and to direct the switch to an alternate antitumor 274	  
agent that can potentially overcome relevant subclonal outgrowth(s) (Figure 3B). Combination 275	  
therapies with two or more directed agents that target horizontal and vertical pathways involved 276	  
in cancer development and survival to delay or prevent tumor outgrowth and resistance by 277	  
preventing potential bypass routes (Figure 3C). For example, the combination of trametinib 278	  
(MEK inhibitor) and dabrafenib (BRAF inhibitor) in metastatic malignant melanoma improved 279	  
patient outcomes from single agent therapy with a progression free survival advantage from 7.3 280	  
months to 11.4 months [67]. It may also be theoretically possible to herd cancer cells down 281	  
particular molecular pathways and thereby artificially drive clonal evolution through predictable 282	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paths using multi-scale mathematical modeling, so as to select for certain subclones that can then 283	  
be targeted (Figure 3D) [68 – 70]. 284	  
 285	  
Finally, there is a pressing need to improve the assessment of clinical trial endpoints. Rather than 286	  
continue to rely on overall survival and progression-free-survival to assess targeted agent 287	  
efficacy, the use of intermediate endpoint biomarkers and advanced functional imaging 288	  
modalities are essential, along with a move away from antiquated traditional response 289	  
assessments. Indeed, tumor reduction may be misleading as a measure of response, especially 290	  
with immunotherapeutics, and alternative considerations should be pursued. 291	  
 292	  
Precision Medicine in Immuno-Oncology  293	  
Precision medicine for immunotherapies, while having the same over-arching principles, 294	  
harbors several major differences to strategies for molecularly targeted agents. Biologic targeted 295	  
therapies directly inhibit cancer aberrations, whereas immunotherapies harness the immune 296	  
system and are thus an indirect form of cancer treatment.  297	  
 298	  
While ‘OMIC technology has driven precision medicine in targeted therapy, the same may not 299	  
be said of immunotherapy, as bona fide driver aberrations have not been found to correlate 300	  
robustly with responses [71]. Immunotherapy has led to superior patient benefit in cancers 301	  
previously resistant to both chemotherapy and targeted therapy strategies, such as advanced 302	  
squamous cell NSCLC, renal cell carcinoma and bladder cancers. However, even in these tumor 303	  
groups, only approximately one in five patients truly appear to benefit from immunotherapy 304	  
[4,72]. This implies an urgent need for better predictive biomarkers of response and resistance so 305	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as to identify those who will benefit and to exclude patients who will not, avoiding potential drug 306	  
toxicities and unnecessary financial burden. PD-L1 expression is the most advanced predictive 307	  
biomarker for PD-1 and PD-L1 inhibitors and is already approved as a companion diagnostic for 308	  
use with pembrolizumab (Merck) and nivolumab (BMS) [5]. However, there is much debate on 309	  
PD-L1 as a biomarker, as selected patients without PD-L1 expression have also been found to 310	  
benefit from immunotherapy, and thus, completely excluding PD-L1 negative patients from 311	  
immune checkpoint inhibitor therapy would be unfair and unethical [73]. There is currently 312	  
interest in monitoring PD-L1 expression changes on tumor cells at different treatment time 313	  
points, as well as investigating it’s significance on tumor-infiltrating lymphocytes and correlating 314	  
such data with patient outcomes [74]. Inter and intra-tumor heterogeneous expression of PD-L1 315	  
has been reported with variations of approximately 25% [75, 76], resulting in sampling errors 316	  
and discrepancies between core biopsies and surgical specimens reported in one study of up to 317	  
48% [77]. This heterogeneity, as discussed previously, remains an ongoing challenge. Mutational 318	  
burden has also been associated with improved patient outcomes to immunotherapy with a 319	  
higher nonsynonymous mutation load, that is a greater volume of functional genomic 320	  
aberrations, associated with improved objective response rate and progression-free survival [78]. 321	  
 322	  
A better understanding of the development of tumor neoantigens, their recognition by the 323	  
immune system and evolution over time has given us the opportunity for further personalization 324	  
of immunotherapeutics with the development of cancer vaccines and cell therapies [79, 80]. 325	  
Identifying increased absolute and subpopulation lymphocyte counts as well as intratumor 326	  
heterogeneity of neoantigens has been associated with increased sensitivity to immune 327	  
checkpoint inhibition and improved overall survival [81, 82].  328	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 329	  
While much research focus has been on immune checkpoint inhibitors, there are several other 330	  
individual-focused immuno-oncology strategies. Adoptive T-cell therapy is the process whereby 331	  
specific T-cells are identified, expanded and infused into the patient, with T-cell receptor 332	  
technology (TCR) allowing recognition of proteins expressed within cancer cells. The changes to 333	  
the immune system as a result of the host’s immune response and the tumor’s effects is known as 334	  
immunoediting. Immunoediting of T-cell mediated neoantigens using adoptive T-cell therapy 335	  
has shown durable responses by overcoming some of the resistance mechanisms of tumors, such 336	  
as loss of neoantigen expression [80]. This would be the epitome of precision medicine in 337	  
immuno-oncology; however, this technology is still in the early phases of clinical testing, and 338	  
much work is still required to confirm its safety and efficacy [83]. Several challenges exist in 339	  
getting T-cells to reach the tumor to effect cytotoxicity; one potential solution is the use of 340	  
chimeric antigen receptor (CAR) T cells. CARs are modified autologous T-cells that are 341	  
genetically modified with synthetic receptors made of signaling elements and antigen binding 342	  
domains of T-cell and B-cell receptors respectively [84]. This allows the CAR to target the 343	  
antigen it has been designed for. Disappointingly, suppression of CARs within the tumor 344	  
microenvironment has resulted in a lack of efficacy in clinical trials. This has led to the 345	  
development of “armored” CARs, which are protected from innate destruction in the tumor 346	  
microenvironment [85].  347	  
 348	  
Modern clinical trial designs for immunotherapies have taken a different route to those for 349	  
targeted agents. Several early phase immunotherapy trials are large “all-comer” studies, which 350	  
incorporate multiple expansion cohorts, resulting in patient numbers ranging from several 351	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hundred to over a thousand patients [73, 86]. This clearly has implications on the time, resources 352	  
and cost of running such large clinical trials. 353	  
 354	  
Concluding Remarks 355	  
Precision medicine, the act of utilizing specific antitumor therapies against molecularly matched 356	  
cancers, is expected to become the paradigm of future cancer medicine. To date, despite high 357	  
expectations, precision medicine has disappointingly only improved patient survival in severally 358	  
molecularly-driven cancers [87 – 89]. Despite advances in modern biotechnologies, including 359	  
NGS platforms and theranostic companion biomarkers, as well as innovative clinical trial 360	  
designs, challenges persist, such as clonal evolution resulting in intratumor and intertumor 361	  
heterogeneity [9] (Outstanding questions box).  362	  
 363	  
In order to address such challenges, rational combination regimens of targeted agents and 364	  
immunotherapies, as well as switch and priming biomarker design strategies should be pursued 365	  
to delay the development of drug resistance and improve antitumor responses (Outstanding 366	  
Questions Box).  In the future, further advances in ‘OMIC-technology and bioinformatics will 367	  
enhance the detection of low-frequency events occurring before and during treatment 368	  
(Outstanding Questions Box). In addition, advances in non-invasive imaging techniques and 369	  
liquid biopsies detecting cfDNA will also permit real-time assessments and identify the 370	  
emergence of resistant clones at earlier time points. Finally, more widespread adoption of 371	  
contemporary clinical trial designs will also accelerate drug and companion predictive biomarker 372	  
development in parallel, while critically improving patient outcomes in cancer medicine [1] 373	  
(Outstanding Questions Box). 374	  
	   18	  
Acknowledgments 375	  
The Drug Development Unit of the Royal Marsden NHS Foundation Trust and The Institute of 376	  
Cancer Research is supported in part by a programme grant from Cancer Research UK. Support 377	  
is also provided by the Experimental Cancer Medicine Centre (to The Institute of Cancer 378	  
Research) and the National Institute for Health Research Biomedical Research Centre (jointly to 379	  
the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research). 380	  
  381	  
	   19	  
References 382	  
1. Brabbek J, Rosel D, Fernandes M. (2016) Pragmatic medicine in solid cancer: a 383	  
translational alternative to precision medicine. Onco. Targets Ther. 9, 1839–1855 doi: 384	  
10.2147/OTT.S103832. 385	  
2. Workman P and de Bono J. (2008) Targeted therapeutics for cancer treatment: major 386	  
progress towards personalized molecular medicine. Curr. Opin. Pharmacol. 8(4), 359-62 387	  
3. Sleijfer S, Ballman K, Verweij J. (2013) The future of drug development? Seeking 388	  
evidence of activity of novel drugs in small groups of patients. J. Clin. Oncol. 31(18), 389	  
2246–2248.  390	  
4. Brahmer J, Reckamp KL, Baas P, et al. (2015) Nivolumab versus Docetaxel in Advanced 391	  
Squamous-Cell Non-Small-Cell Lung Cancer. N. Engl. J. Med. 373(2), 123-35. doi: 392	  
10.1056/NEJMoa1504627 393	  
5. Borghaei H, Paz-Ares L, Horn L, et al. (2015) Nivolumab versus Docetaxel in Advanced 394	  
Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 373(17), 1627-39. doi: 395	  
10.1056/NEJMoa1507643. 396	  
6. Motzer RJ, Escudier B, McDermott DF, et al. (2015) Nivolumab versus Everolimus in 397	  
Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 373(19), 1803-13. doi: 398	  
10.1056/NEJMoa1510665.  399	  
7. Weinstein IB. (2002) Cancer. Addiction to oncogenes--the Achilles heal of cancer 400	  
Science. 297(5578), 63-4. 401	  
8. Vogelstein B, Papadopoulos N, Velculescu VE, et al. (2013) Cancer genome landscapes. 402	  
Science. 339, 1546–1558 403	  
	   20	  
9. Merlo LM, Pepper JW, Reid BJ, et al. (2006) Cancer as an evolutionary and ecological 404	  
process. Nat. Rev. Cancer. 6, 924–935 405	  
10. Greaves M and Maley CC. (2012) Clonal evolution in cancer. Nature. 481, 306–313. 406	  
11. Suzuki K, Ojima M, Kodama S, Watanabe M. (2003) Radiation-induced DNA damage 407	  
and delayed induced genomic instability. Oncogene. 22, 6988–6993 408	  
12. Johnson BE, Mazor T, Hong C et al. (2014) Mutational analysis reveals the origin and 409	  
therapy-driven evolution of recurrent glioma. Science. 343, 189–193 410	  
13. Burrell RA, McGranahan N, Bartek J, et al. (2013) The causes and consequences of 411	  
genetic heterogeneity in cancer evolution. Nature, 501, 338–345 412	  
14. Gerlinger M, Rowan AJ, Horswell S, et al. (2012) Intratumor heterogeneity and branched 413	  
evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883–892.  414	  
15. Diaz LA, Jr, Williams RT, Wu J et al. (2012) The molecular evolution of acquired 415	  
resistance to targeted EGFR blockade in colorectal cancers. Nature. 486, 537–540. 416	  
16. McGranahan N, Favero F, de Bruin EC, et al. (2015) Clonal status of actionable driver 417	  
events and the timing of mutational processes in cancer evolution. Sci. Transl. Med. 7 418	  
(283), 283ra54 419	  
17. Baca SC, Prandi D, Lawrence MS, et al. (2013) Punctuated evolution of prostate cancer 420	  
genomes. Cell, 153, 666–677 421	  
18. Shah SP, Roth A, Goya R, et al. (2012) The clonal and mutational evolution spectrum of 422	  
primary triple-negative breast cancers. Nature, 486, 395–399 423	  
19. Meacham CE and Morrison SJ. (2013) Tumor heterogeneity and cancer cell plasticity. 424	  
Nature. 501(7467), 328–337  425	  
	   21	  
20. Turner NC and Reis-Filho JS. (2012) Genetic heterogeneity and cancer drug resistance. 426	  
Lancet Oncol. 13(4), e178–e185.  427	  
21. Lee W, Jiang Z, Liu J, et al. (2010) The mutation spectrum revealed by paired genome 428	  
sequences from a lung cancer patient. Nature, 465(7297), 473-7. doi: 429	  
10.1038/nature09004. 430	  
22. Cantrell MA and Kuo CJ. (2015) Organoid modeling for cancer precision medicine. 431	  
Genome Med. 7(1), 32. doi:10.1186/s13073-015-0158-y 432	  
23. Crystal AS, Shaw AT, Sequist LV, et al. (2014) Patient-derived models of acquired 433	  
resistance can identify effective drug combinations for cancer. Science. 346, 1480–6.  434	  
24. Forbes SA, Bindal N, Bamford S, et al. (2011) COSMIC: mining complete cancer 435	  
genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-436	  
D950. doi:10.1093/nar/gkq929 437	  
25. Van Allen EM, Wagle N, Sucker A, et al. (2014) The genetic landscape of clinical 438	  
resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4, 94–109 439	  
26. Catenacci DV, Amico AL, Nielsen SM, et al. (2015) Tumor genome analysis includes 440	  
germline genome: are we ready for surprises? Int. J. Cancer. 36, 1559-67  441	  
27. Hudson TJ, Anderson W, Artez A, et al. (2010) International Cancer Genome 442	  
Consortium. International network of cancer genome projects. Nature. 464(7291), 993–443	  
998.  444	  
28. Barretina J, Caponigro G, Stransky N, et al. (2012) The Cancer Cell Line Encyclopedia 445	  
enables predictive modelling of anticancer drug sensitivity. Nature. 483, 603–607. 446	  
29. Kandoth C, McLellan MD, Vandin F, et al. (2013) Mutational landscape and significance 447	  
across 12 major cancer types. Nature. 502, 333–339 448	  
	   22	  
30. Lawrence MS, Stojanov P, Mermel CH, et al. (2014) Discovery and saturation analysis of 449	  
cancer genes across 21 tumor types. Nature. 505, 495–501 450	  
31. Iyer MK, Niknafs YS, Malik R, et al. (2015) The landscape of long noncoding RNAs in 451	  
the human transcriptome, Nat. Genet. 47(3), 199-208. 452	  
32. Moskalev EA, Frohnauer J, Merkelbach-Bruse S, et al. (2014) Sensitive and specific 453	  
detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) 454	  
specimens by multiplex amplicon RNA massive parallel sequencing. Lung Cancer 84(3), 455	  
215-21.  456	  
33. Fernandez-Cuesta L, Sun R, Menon R, et al. (2015) Identification of novel fusion genes 457	  
in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biol 458	  
16, 7.  459	  
34. Pentheroudakis G, Pavlidis N, Fountzilas G, et al. (2013) Novel microRNA-based assay 460	  
demonstrates 92% agreement with diagnosis based on the clinicopathologic and 461	  
management data in a cohort of patients with carcinoma of unknown primary. Mol. 462	  
Cancer. 12, 57. 463	  
35. Scott DE, Bayly AR, Abell C, et al. (2016) Small molecules, big targets: drug discovery 464	  
faces the protein-protein interaction challenge. Nat. Rev. Drug Discovery. 465	  
doi:10.1038/nrd.2016.29 [Epub ahead of print] 466	  
36. Pillai S and Chellappan SP. (2015) ChIP on chip and ChIP-Seq assays: genome wide 467	  
analysis of transcription factor binding and histone modifications. Methods Mol. Biol. 468	  
1288, 447-72. 469	  
37. Jin SG, Xiong W, Wu X, et al. (2015) The DNA methylation landscape of human 470	  
melanoma. Genomics. 106(6), 322-30. 471	  
	   23	  
38. Earp MA and Cunningham JM. (2015) DNA methylation changes in epithelial ovarian 472	  
cancer histotypes. Genomics. 106(6), 311-21. 473	  
39. de Bruin EC, McGranahan N, Mitter R, et al. (2014) Spatial and temporal diversity in 474	  
genomic instability processes defines lung cancer evolution. Science. 346(6206), 251–6. 475	  
40. Swanton C. (2012) Intratumor heterogeneity: evolution through space and time. Cancer 476	  
Res. 72(19), 4875–82. 477	  
41. Alix-Panabieres C and Pantel K. (2014) Challenges in circulating tumor cell research. 478	  
Nat. Rev. Cancer. 14(9), 623–31. 479	  
42. Heitzer E, Auer M, Gasch C, et al. (2013) Complex tumor genomes inferred from single 480	  
circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 481	  
73(10), 2965–75. 482	  
43. Lohr JG, Adalsteinsson VA, Cibulskis K, et al. (2014) Whole-exome sequencing of 483	  
circulating tumor cells provides a window into metastatic prostate cancer. Nat 484	  
Biotechnol. 32(5), 479–84. 485	  
44. Scher HI, Heller G, Molina A, et al. (2015) Circulating tumor cell biomarker panel as an 486	  
individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J. 487	  
Clin. Oncol. 33(12), 1348–55. 488	  
45. Lebofsky R, Decraene C, Bernard V, et al. (2015) Circulating tumor DNA as a non-489	  
invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine 490	  
in a prospective trial across all tumor types. Mol. Oncol. 9(4), 783–790.  491	  
46. Thierry AR, Mouliere F, El Messaoudi S, et al. (2014) Clinical validation of the detection 492	  
of KRAS and BRAF mutations from circulating tumor DNA. Nat. Med. 20, 430-5. 493	  
	   24	  
47. Dawson SJ, Tsui DW, Murtaza M, et al. (2013) Analysis of circulating tumor DNA to 494	  
monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199-209. 495	  
48. Frenel JS, Carreira S, Goodall J, et al. (2015) Serial next generation sequencing of 496	  
circulating cell free DNA evaluating tumor clone response to molecularly targeted drug 497	  
administration. Clin. Cancer Res. 21(20), 4586–4596. doi:10.1158/1078-0432.CCR-15-498	  
0584. 499	  
49. Oxnard GR, Paweletz CP, Kuang Y, et al. (2014) Noninvasive detection of response and 500	  
resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of 501	  
cell-free plasma DNA. Clin. Cancer Res. 20(6), 1698–705. 502	  
50. Bettegowda C, Sausen M, Leary RJ, et al. (2014) Detection of circulating tumor DNA in 503	  
early- and late-stage human malignancies. Sci. Transl. Med. 6(224), 224ra24.  504	  
51. Janku F, Vibat CR, Kosco K, et al. (2014) BRAF V600E mutations in urine and plasma 505	  
cell-free DNA from patients with Erdheim-Chester disease. Oncotarget. 5(11), 3607–10. 506	  
52. Wakelee HA, Gadgeel SM, Goldman JW, et al. (2016) Epidermal growth factor receptor 507	  
(EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung 508	  
cancer (NSCLC) patients (pts) treated with rociletinib. J. Clin. Oncol. 34 (15) suppl, 509	  
abstract 9001 510	  
53. Thress KS, Paweletz CP, Felip E, et al. (2015) Acquired EGFR C797S mutation mediates 511	  
resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 512	  
21(6), 560–2. 513	  
54. Murtaza M, Dawson SJ, Tsui DW, et al. (2013) Non-invasive analysis of acquired 514	  
resistance to cancer therapy by sequencing of plasma DNA. Nature. 497, 108–12 515	  
55. Arkenau HT, Kefford R, Long GV. (2011) Targeting BRAF for patients with melanoma. 516	  
Br. J. Cancer. 104(3), 392- 398. 517	  
	   25	  
56. Chapman PB, Hauschild A, Robert C, et al. (2011) Improved survival with vemurafenib 518	  
in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507-2516. 519	  
57. Shaw AT, Kim DW, Nakagawa K, et al. (2013) Crizotinib versus chemotherapy in 520	  
advanced ALK-positive lung cancer. N. Engl. J. Med. 368(25), 2385-2394. 521	  
58. Kantarjian H, Sawyers C, Hochhaus A, et al. (2002) International STI571 CML Study 522	  
Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic 523	  
myelogenous leukemia. N. Engl. J. Med. 346(9), 645–652. 524	  
59. Pegram MD, Lipton A, Hayes DF, et al. (1998) Phase II study of receptor-enhanced 525	  
chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal 526	  
antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast 527	  
cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16(8), 2659–2671. 528	  
60. Hay M, Thomas DW, Craighead JL, et al. (2014) Clinical development success rates for 529	  
investigational drugs. Nat. Biotechnol. 32, 40-51. 530	  
61. Mick R and Ratain MJ. (1993) Model-guided determination of maximum tolerated dose 531	  
in phase 1 clinical trials: evidence for increased precision. J. Natl. Cancer. Inst. 85, 217-532	  
223. 533	  
62. Wong KM, Capasso A, Eckhardt SG. (2015) The changing landscape of phase 1 trials in 534	  
oncology. Nat. Rev. Clin. Oncol. 13, 106-117; doi:10.1038/nrclinonc.2015.194. 535	  
63. Roda D, Jimenez B, Banerji U. (2016) Are doses and schedule of small molecule targeted 536	  
anticancer drugs recommended by phase 1 studies realistic? Clin. Cancer Res. 22(9), 537	  
2127-32 doi: 10.1158/1078-0432.CCR-15-1855. 538	  
64. Simon R, Freidlin B, Rubinstein L, et al. (1997) Accelerated titration designs for phase 1 539	  
clinical trials in oncology. J. Natl. Cancer Inst. 89, 1138-1147. 540	  
	   26	  
65. Jaki T, Clive S, Weir CJ. (2013) Principles of dose finding studies in cancer: a 541	  
comparison of trial designs. Cancer Chemother. Pharmacol. 71, 1107-1114. 542	  
66. Le Tourneau C, Lee JJ, Siu LL. (2009) Dose Escalation Methods in Phase I Cancer 543	  
Clinical Trials. J. Natl. Cancer Inst. 101(10), 708-20. 544	  
67. Robert C, Karaszewska B, Schachter J et al. (2015) Improved overall survival in 545	  
melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30-39. 546	  
68. Lipinski KA, Barber LJ, Davies MN, et al. (2016) Cancer Evolution and the Limits of 547	  
Predictability in Precision Cancer Medicine. Trends Cancer. 2(1), 49-63. 548	  
doi:10.1016/j.trecan.2015.11.003. 549	  
69. Wang E, Zaman N, Mcgee S, et al. (2015) Predictive genomics: a cancer hallmark 550	  
network framework for predicting tumor clinical phenotypes using genome sequencing 551	  
data. Semin. Cancer Biol. 30: 4-12  552	  
70. William MJ, Werner B, Barnes CP, et al. (2016) Identification of neutral tumor evolution 553	  
across cancer types. Nat Genet. 48, 238-244. doi:10.1038/ng.3489 554	  
71. Weber JS, D'Angelo SP, Minor D, et al. (2015). Nivolumab versus chemotherapy in 555	  
patients with advanced melanoma who progressed after anti-CTLA-4 treatment 556	  
(CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 557	  
16(4), 375-84. doi: 10.1016/S1470-2045(15)70076-8.  558	  
72. Rosenberg JE, Hoffman-Censits J, Powles T, et al. (2016) Atezolizumab in patients with 559	  
locally advanced and metastatic urothelial carcinoma who have progressed following 560	  
treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. 561	  
Lancet. 387(10031), 1909-20. doi: 10.1016/S0140-6736(16)00561-4.  562	  
73. Herbst RS, Soria JC, Kowanetz M, et al. (2014) Predictive correlates of response to the 563	  
	   27	  
anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515(7528), 563-7. doi: 564	  
10.1038/nature14011. 565	  
74. Tumeh PC, Harview CL, Yearley JH, et al. (2014) PD-1 blockade induces responses by 566	  
inhibiting adaptive immune resistance Nature. 515(7528), 568-71. doi: 567	  
10.1038/nature13954. 568	  
75. McLaughlin J, Han G, Schalper KA et al. (2016) Quantitative assessment of the 569	  
heterogeneity of PD-L1 expression in NSCLC. JAMA Oncol. 2(1), 46-54 570	  
76. Callea M, Albiges L, Gupta M, et al. (2015) Differential expression of PD-L1 between 571	  
primary and metastatic sites in clear cell renal cell carcinoma. Cancer. Immunol. Res. 572	  
3(10), 1158-64 573	  
77. Illie M, Long-Mira E, Bence C, et al. (2016) Comparative study of the PD-L1 status 574	  
between surgically resected specimen and matched biopsies of NSCLC patients reveal 575	  
major discordances: a potential issue for anti-PDL1 therapeutic strategies. Ann. Oncol. 576	  
27(1), 147-153 577	  
78. Rizvi NA, Hellman MD, Snyder A, et al. (2015) Cancer Immunology. Mutational 578	  
landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 579	  
348 (6230), 124-8 580	  
79. Schumacher TN and Schreiber RD. (2015) Neoantigens in cancer immunotherapy. 581	  
Science. 348, 69-74 582	  
80. Verdegaal EME, de Miranda NFCC, Visser M, et al. (2016) Neoantigen landscape 583	  
dynamics during human melanoma–T cell interactions. Nature. doi:10.1038/nature18945. 584	  
Epub ahead of print 585	  
81. McGranahan N, Furness AJ, Rosenthal R et al. (2016) Clonal neoantigens elicit T cell 586	  
	   28	  
immunoreactivity and sensitivity to immune checkpoint blockade. Science. 351(6280), 587	  
1463-9. doi: 10.1126/science.aaf1490. 588	  
82. Martens A, Wistuba-Hamprecht K, Yuan J, et al. (2016). Increases in absolute 589	  
lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical 590	  
outcome of melanoma patients treated with ipilimumab. Clin. Cancer Res. pii: 591	  
clincanres.0249.2016. [Epub ahead of print] 592	  
83. Stromnes IM, Schmitt TM, Chapuis AG, et al. (2014) Re-adapting T cells for cancer 593	  
therapy: from mouse models to clinical trials. Immunol. Rev. 257(1), 145-64. doi: 594	  
10.1111/imr.12141. 595	  
84. Sadelain M, Riviere I, Brentjens R. (2003) Targeting tumors with genetically enhanced T 596	  
lymphocytes. Nat. Rev. Cancer. 3(1), 35-45. 597	  
85. Pegram HJ, Park JH, Brentjens RJ. (2014) CD28z CARs and armored CARs. Cancer J. 598	  
20(2), 127-33. doi: 10.1097/PPO.0000000000000034. 599	  
86. Topalian SL, Hodi FS, Brahmer JR, et al. (2012) Safety, activity, and immune correlates 600	  
of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-54. doi: 601	  
10.1056/NEJMoa1200690.  602	  
87. Hoag H. (2011) Cancer drugs should add months, not weeks, say experts. Nature Med. 603	  
17(1), 7 604	  
88. Ward, A. (2015) Healthcare: counting the cost of cancer. Financial Times, January 15, 605	  
2015 606	  
89. Mailankody S and Prasad V. (2015) Five years of cancer drug approvals innovation, 607	  
efficacy, and costs. JAMA Oncol. 1(4), 539–540. 608	  
	   29	  
90. Snyder M, Du J, Gerstein M. (2010) Personal genome sequencing: current approaches 609	  
and challenges. Genes Dev. 24, 423–431. 610	  
  611	  
	   30	  
Figure 1. Branched clonal evolution with resultant intratumor and intertumor heterogeneity 612	  
• Graphic of branched clonal evolution with resultant intratumor and intertumor 613	  
heterogeneity. Selection pressures and genomic instability can lead to subclonal tumor 614	  
outgrowths and development of further aberrations, both driver and passenger 615	  
• Single biopsies from single sites can result in imprecise management decisions with 616	  
molecularly targeted therapies that may not target other tumor sites due to intertumor 617	  
heterogeneity. 618	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Figure	  2.	  Tumor	  mass	  made	  up	  of	  distinct	  clones	  and	  subclones.	  This	  leads	  to	  three	  very	  different	  621	   biopsy	  specimens,	  as	  depicted	  in	  separate	  boxes	  1	  –	  3.	  This	  highlights	  the	  importance	  of	  multiple	  622	   biopsies	  from	  different	  locations	  within	  a	  single	  tumor	  specimen	  to	  get	  a	  truer	  reflection	  of	  the	  623	   underlying	  complexity	  624	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Figure	  3.	  Potential	  precision	  medicine	  treatment	  strategies	  to	  improve	  tumor	  response	  to	  627	   molecularly	  targeted	  agents:	  a)	  biopsy-­‐driven;	  b)	  switch;	  c)	  combination;	  and	  d)	  priming	  628	   Four	  examples	  of	  precision	  medicine	  treatment	  approaches	  guided	  by	  sequential	  tumor	  biopsies,	  629	   clinical	  and	  radiological	  progression	  decisions	  and/or	  biomarker	  assessment	  630	   3A.	  Sequential	  targeted	  treatments	  based	  upon	  tumor	  biopsy	  results	  631	   3B.	  Targeted	  treatment	  switch	  strategies	  led	  by	  measured	  biomarker	  assessments	  632	   3C.	  Targeted	  therapy	  combination	  therapy	  led	  by	  biomarker	  assessment	  and/or	  biopsy	  results	  633	   from	  NGS	  or	  other	  platforms	  634	   3D.	  Priming	  approach	  purposefully	  encourages	  tumor	  differentiation	  into	  specific	  and	  actionable	  635	   subclones	  that	  can	  then	  be	  exposed	  to	  molecularly	  targeted	  agents	  636	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Trial	  name	  
Precision	  
Medicine	  
Trial	  type	  
Investigational	  
agent	  &	  target	  if	  
known	  
Inclusion	  
criteria	  
Target	  
recruitme
nt	  
(n)	  
Sponsor	  /	  
Country	  
NCT	  
identifier	  
ALCHEMIST	  Adjuvant	  Lung	  Cancer	  Enrichment	  Marker	  Identification	  and	  Sequencing	  Trial	  
Umbrella	  	   To	  facilitate	  accrual	  to	  adjuvant	  Intergroup	  studies,	  E4512	  (ALK	  fusion	  mut	  &	  crizotinib)	  &	  A081105	  (erlotinib	  &	  EGFR	  mut)	  
Operable	  Non-­‐squamous	  NSCLC	  (Stage	  IB-­‐IIIA)	   6000	  –	  8000	   NCI	  /	  ECOG-­‐ACRIN	  Cancer	  Research	  Group	  	  
NCT02194738,	  NCT02193282,	  NCT02201992	  	  
AURORA	  	  Aiming	  to	  understand	  molecular	  aberrations	  in	  metastatic	  breast	  cancer	  
Other	  	   Biopsy	  (repeat),	  biomarker	  &	  NGS	  analysis	   Metastatic	  breast	  cancer	   1300	   Breast	  International	  Group	  (BIG)	  	  UK	  /	  Europe	  
NCT02102165	  
BATTLE-­‐2	  	  Biomarker-­‐Integrated	  Targeted	  Therapy	  Study	  
Umbrella	   AZD6244	  +	  MK-­‐2206	  
Erlotinib + MK-2206 Sorafenib	   Stage	  IIIB	  or	  IV	  NSCLC	  progressed	  on	  first	  line	  treatment	  
450	   MD	  Anderson	  Cancer	  Centre/NCI	  	  USA	  
NCT01248247	  
DARWIN	  II	  Deciphering	  Antitumor	  Response	  and	  Resistance	  With	  INtratumor	  heterogeneity	  	  
Other	  	  To	  assess	  if	  intra-­‐tumor	  heterogeneity	  is	  associated	  with	  PFS	  
Alectinib:	  ALK/RET	  gene	  rearrangement	  MPDL3280A:	  no	  actionable	  mut	  &	  PD-­‐L1+	  or	  PDL1-­‐	  after	  1	  line	  of	  chemo	  Trastuzumab	  emtansine:	  HER2	  amplification	  Vemurafenib:	  BRAFV600	  
Relapsed	  NSCLC	   119	   Roche	  	  UK	   NCT02314481	  
Exceptional	  
Responders	  study	  	   Other	  	  Hypothesis	  generation	  for	  reasons	  for	  exceptional	  response	  to	  cancer	  treatment	  
Biopsy,	  biomarker	  &	  NGS	  analysis	   Patients	  with	  a	  complete	  response	  or	  partial	  response	  of	  at	  least	  6	  months	  where	  expected	  ORR	  typically	  <10%	  
300	  	   NCI	  	  USA	   NCT02243592,	  NCT02496195	  
FOCUS4	  	   Umbrella	   BRAF	  +	  EGFR	  +/-­‐	  MEK	  inhibitor:	  BRAF	  mut	  Aspirin:	  PI3KCA	  mut	  AKT	  +	  MEK	  inhibitors:	  KRAS	  or	  NRAS	  mut	  HER1,	  2,	  3	  inhibitor:	  All	  wild	  type	  with	  PTEN	  expression	  Capecitabine:	  nonstratified	  
Metastatic	  colorectal	  cancer	  post	  standard	  1st	  line	  therapy	  
4500-­‐5500	  	   MRC/CRUK	  	  UK	  
ISRCTN	  Clinical	  Trials	  Register	  9006156	  
GEMM	  Genomics-­‐Enabled	  Medicine	  for	  Melanoma	  
Umbrella	   Molecularly	  matched	  targeted	  agents	  vs	  physician’s	  choice	  of	  therapy	   BRAF	  wild-­‐type	  Stage	  IIIa-­‐IV	  metastatic	  melanoma	  after	  immunotherapy	  
136	   NCI	  	  USA	   NCT02094872	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I-­‐SPY2	  Investigation	  of	  Serial	  Studies	  to	  Predict	  Your	  Therapeutic	  Response	  With	  Imaging	  and	  Molecular	  Analysis	  2	  
Umbrella	  Neoadjuvant	  and	  Personalized	  Adaptive	  Novel	  Agents	  to	  Treat	  Breast	  Cancer	  
AMG	  386	  +/-­‐	  trastuzumab	  AMG	  479	  (Ganitumab)	  +	  metformin	  ABT-­‐888	  Ganetespib	  Neratinib	  PLX3397	  +	  paclitaxel	  Pembrolizumab	  +	  paclitaxel	  Trastuzumab	  +	  pertuzumab	  T-­‐DM1	  +	  pertuzumab	  MK-­‐2206	  +/-­‐	  trastuzumab	  Comparator	  arm	  (paclitaxel	  +	  doxorubicin	  +	  cyclophosphamide	  +/-­‐	  trastuzumab)	  
Neoadjuvant	  breast	  cancer	   1200	  	   QuantumLeap	  Healthcare	  Collaborative	  	  USA,	  Canada	  
NCT01042379	  
Lung-­‐MAP	  Lung	  Cancer	  Master	  Protocol	   Umbrella	   AZD4547:	  FGFR1,	  FGFR2,	  FGFR3	  Docetaxel:	  comparator	  arm	  Erlotinib	  +/-­‐	  rilotumumab:	  HGF/c-­‐MET	  MEDI4736	  (durvalumab):	  	  no	  active	  drug-­‐biomarker	  option	  Nivolumab	  +/-­‐	  ipilimumab:	  no	  active	  drug-­‐biomarker	  option	  Palbociclib:	  CDK4/6,	  CCND1,2	  &	  3	  Taselisib:	  PI3KCA	  expression	  
Recurrent	  advanced	  squamous	  NSCLC	  	   10000	  	   SWOG/NCI	  	  USA	   NCT02154490	  
MATCH	  Molecular	  Analysis	  for	  Therapy	  Choice	   Basket	   Afatinib:	  HER2;	  EGFR	  mut	  	  AKT	  inhibitor	  AZD5363:	  Akt	  mut	  Binimetinib:	  	  NRAS	  mut	  in	  codon	  12,	  13,	  or	  61	  	  Crizotinib:	  MET	  amp/exon	  14	  del;	  ALK	  trans;	  ROS1	  trans	  /	  inv	  Dabrafenib	  (+	  trametinib):	  BRAF	  V600	  Dasatinib:	  DDR2	  S768R,	  I638F	  or	  L239R	  mut	  Defactinib:	  NF2	  inactivating	  mut	  FGFR	  inhibitor	  AZD4547:	  	  FGFR1-­‐3	  amp,	  mut	  or	  trans	  Nivolumab:	  Mismatch	  repair	  deficiency	  Osimertinib	  (AZD9291):	  EGFR	  T790M	  mut	  Palbociclib:	  	  CCND1,	  2,	  or	  3	  amp	  +	  Rb	  expression	  by	  IHC	  PI3Kbeta	  inhibitor	  GSK2636771:	  PTEN	  mut,	  del,	  expression,	  loss	  Sunitinib	  maleate:	  cKIT	  exon	  9,11,13	  or	  14	  mut	  Taselisib:	  PTEN	  loss;	  PI3K	  mut	  or	  amp	  without	  RAS	  mut	  Trametinib:	  BRAF	  V600	  (with	  dabrafenib);	  BRAF	  fusion	  or	  non-­‐V600;	  NF1	  mut;	  GNAQ	  or	  GNA11	  mut	  Trastuzumab	  emtansine:	  HER2	  amp	  Vismodegib:	  	  SMO	  or	  PTCH1	  mutation	  
Solid	  tumors	  &	  lymphoma	  post	  progression	  on	  standard	  therapy	  
5000	   NCI	  /	  ECOG-­‐ACRIN	  	  USA	  
NCT02465060	  
MPACT	  Molecular	  Profiling-­‐based	  Assignment	  of	  Cancer	  Therapy	  
Basket	   Everolimus:	  PI3K	  pathway	  defect	  MK-­‐1775	  (Wee1	  inhibitor)	  +	  carboplatin:	  	  DNA	  pathway	  repair	  defects	  Temozolomide	  +	  veliparib	  (ABT-­‐888;	  PARP	  inhibitor):	  	  DNA	  repair	  pathway	  defects	  Trametinib	  DMSO:	  	  Ras/Raf/Mek	  pathway	  mut	  
Advanced	  solid	  tumors	   180	  	   NCI	  	  USA	   NCT01827384	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MyPathway	   Basket	   Erlotinib	  Trastuzumab	  +	  Pertuzumab	  Vemurafenib	  Vismodegib	   Refractory	  metastatic	  cancer	  with	  mut	  or	  gene	  abnormalities	  predictive	  of	  response	  to	  [below]	  
500	   Roche/Genentech	  	  USA	  
NCT02091141	  
National	  Lung	  
Matrix	  Trial	   Umbrella	   AZD4547	  (FGFR	  inhibitor)	  AZD2014	  (MTORC1/2	  inhibitor)	  AZD5363	  (AKT	  inhibitor)	  AZD9291	  (EGFRm+	  T790M+	  inhibitor)	  Crizotinib	  (ALK	  /	  MET	  /	  ROS1	  inhibitor)	  MEDI4736	  (anti-­‐PDL1)	  Palbociclib	  (CDK4/6	  inhibitor)	  Selumetinib	  (MEK	  inhibitor)	  +	  doectaxel	  
Stage	  IIIB	  or	  IV	  NSCLC	   2000	   CRUK	  UK	   NCT02664935	  
SAFIR02	  Efficacy	  of	  Targeted	  Drugs	  Guided	  by	  Genomic	  Profile	  in	  Metastatic	  NSCLC	  Patients	  
Umbrella	  	   Targeted therapy substudy 1 AZD2014	  (mTOR	  inhibitor) AZD4547	  (FGFR	  inhibitor)	  AZD5363	  (AKT	  inhibitor)	  AZD8931	  (HER2,	  EGFR	  inhibitor)	  Erlotinib	  (standard	  maintenance	  for	  squamous	  NSCLC)	  MEDI4736	  (PD-­‐L1	  inhibitor)	  Pemetrexed	  (standard	  maintenance	  for	  non-­‐squamous	  NSCLC)	  Selumetinib	  (MEK	  inhibitor)	  Vandetanib	  (VEGFR,	  EGFR	  inhibitor)	  
Immune substudy 2 Maintenance	  MEDI4736:	  no	  actionable	  genomic	  alterations	  vs	  standard	  maintenance	  
Advanced	  NSCLC	  (vs	  standard	  of	  care)	   650	   UNICANCER	  	  France	  
NCT02117167	  
SIGNATURE	  program	   Basket	   LEE011:	  CDK4/6,	  cyclin	  D1/3	  or	  p16	  gene	  alterations	  Ceritinib	  (LDK378):	  ALK	  or	  ROS1	  alterations	  BGJ398:	  FGFR	  gene	  alterations	  	  
Metastatic	  cancer	  refractory	  to	  standard	  therapy	  
100	  per	  trial	   Novartis	  	  USA	   NCT02187783,	  NCT02186821	  
TAPUR	  Targeted	  Agent	  and	  Profiling	  Utilization	  Registry	  
Basket	   Axitinib:	  VEGFR	  mut,	  amp,	  overexpression	  Bosutinib:	  Bcr-­‐Abl,	  SRC,	  LYN,	  LCK	  mut	  Cetuximab:	  KRAS,	  NRAS	  &	  BRAF	  wildtype	  Crizotinib:	  ALK,	  ROS1	  &	  MET	  mut	  Dasatinib:	  Bcr-­‐Abl,	  SRC,	  KIT,	  PDGFRB,	  EPHA2,	  FYN,	  LCK,	  YES1	  mut	  Erlotinib:	  EGFR	  mut	  Olaparib:	  Germline	  or	  somatic	  BRCA1	  /	  BRCA2	  inactivating	  mut;	  ATM	  mut	  or	  del	  Palbociclib:	  CDKN2A/p16	  loss;	  CDK4	  &	  CDK6	  amp	  Pembrolizumab:	  POLE/POLD1	  mut	  Regorafenib:	  RET,	  VEGFR1,	  VEGFR2,	  VEGFR3,	  KIT,	  PDGFR-­‐beta,	  RAF-­‐1,	  BRAF	  mut/amp	  Sunitinib:	  CSF1R,	  PDGFR,	  VEGFR	  mut	  Temsirolimus:	  mTOR	  or	  TSC	  mut	  Trastuzumab	  +	  pertuzumab:	  
Advanced	  solid	  tumors,	  multiple	  myeloma	  and	  B-­‐cell	  non-­‐Hodgkin	  lymphoma	  	  
1030	  	   ASCO	  	  USA	   NCT02693535	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Table	  1.	  Currently	  recruiting	  major	  precision	  medicine	  trials	  (alphabetical	  order)	  641	   	  642	   Abbreviations	  (alphabetical):	  amp:	  amplification;	  ASCO:	  American	  Society	  of	  Clinical	  Oncology;	  CRUK:	  Cancer	  643	   Research	  United	  Kingdom;	  del:	  deletion;	  ECOG-­‐ACRIN:	  	  Eastern	  Cooperative	  Oncology	  Group	  (ECOG)	  and	  644	   American	  College	  of	  Radiology	  Imaging	  Network	  (ACRIN);	  EGFR:	  epidermal	  growth	  factor	  receptor	  1;	  645	   EGFRm+:	  EGFR	  mutant;	  HER2:	  human	  epidermal	  growth	  factor	  receptor	  2;	  inv:	  inversion;	  MRC:	  Medical	  646	   Research	  Council;	  mut:	  mutation;	  NGS:	  next	  generation	  sequencing;	  NCI:	  National	  Cancer	  Institute;	  NSCLC:	  647	   non	  small	  cell	  lung	  cancer;	  ORR:	  overall	  response	  rate;	  PD-­‐L1:	  programmed	  cell	  death	  ligand	  1;	  PFS:	  648	   progression	  free	  survival;	  SWOG:	  South	  Western	  Oncology	  Group	  ;	  trans:	  translocation;	  UK:	  United	  Kingdom;	  649	   USA:	  United	  States	  of	  America;	  WIN:	  Worldwide	  Innovative	  Network	  650	   	   	  651	  
HER2	  amp	  emurafenib	  +	  Cobimetinib:	  BRAF	  V600E	  mut	  Vismodegib:	  PTCH1	  del	  or	  inactivating	  mut	  
TRACERx	  Tracking	  NSCLC	  Evolution	  through	  therapy	  (Rx)	  
Other	  	  To	  study	  NSCLC	  evolutionary	  genomic	  landscape	  between	  primary	  and	  metastatic	  sites	  &	  intratumor	  heterogeneity	  
Biopsy	  (repeat),	  biomarker	  &	  NGS	  analysis	   Patients	  with	  early	  stage	  I-­‐IIIA	  NSCLC	  eligible	  for	  surgery	  
842	  	   CRUK	  	  UK	   NCT01888601	  
WINTHER	  	  Worldwide	  Innovative	  Networking	  Therapeutics	  
Basket	   Treatment	  with	  matched	  targeted	  therapies	  available	  on	  the	  market	  or	  on	  clinical	  trials	   Metastatic	  cancer	  with	  available	  histologic	  normal	  counterpart	  
200	  	   WIN	  consortium	  	  France,	  Spain,	  Israel,	  USA,	  Canada	  
NCT01856296	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TRENDS	  BOX	  652	  
	  	  	  653	  
Precision	  medicine	  in	  oncology	  has	  been	  advanced	  by	  the	  discovery	  and	  development	  of	  654	   sophisticated	  and	  modern	  next	  generation	  sequencing	  technologies	  	  655	   	  656	   Clonal	  evolution,	  intertumor	  and	  intratumor	  heterogeneity	  are	  important	  challenges	  to	  address	  to	  657	   achieve	  success	  in	  precision	  medicine	  658	   	  659	   Studies	  to	  modulate	  the	  cancer	  mutational	  landscape	  by	  applying	  artificial	  selection	  pressures	  or	  660	   altering	  the	  tumor	  microenvironment	  are	  ongoing	  	  661	   	  662	   Experience	  with	  immunotherapies	  and	  our	  knowledge	  of	  their	  effects	  on	  the	  cancer	  cell	  continue	  to	  663	   advance,	  revealing	  the	  importance	  of	  neoantigens	  and	  the	  need	  for	  robust	  predictive	  biomarkers	  of	  664	   response	  and	  resistance 	  665	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OUTSTANDING	  QUESTIONS	  BOX	  666	   1. Can	  we	  develop	  realistic	  cancer	  evolution	  models	  to	  assess	  sensitivity	  to	  molecularly	  667	   targeted	  agents?	  668	   2. How	  can	  the	  development	  of	  validated	  companion	  biomarkers	  for	  molecularly	  targeted	  669	   agents	  and	  immunotherapies	  be	  optimized?	  670	   3. Can	  we	  control,	  restrain	  or	  predict	  clonal	  evolution,	  intertumor	  and	  intratumor	  671	   heterogeneity?	  672	   4. What	  degree	  of	  functional	  validation	  is	  required	  to	  ensure	  that	  cancer	  aberrations	  identified	  673	   by	  next	  generation	  sequencing	  are	  clinically	  significant?	  	  674	   5. What	  proportion	  of	  tumors	  harbor	  multiple	  driver	  aberrations	  that	  are	  challenging	  to	  675	   address	  with	  precision	  medicine	  strategies?	   	  676	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GLOSSARY 677	  
Avatars: a mouse implanted with cells or tissue freshly extracted from a human being, to test drug 678	  
therapies for an individual patient or to study a disease process 679	  
Basket trials: test the effect of a single drug on a single mutation in a variety of cancer types; can also 680	  
screen multiple drugs across many cancer types.  681	  
Biomarker: a characteristic that is objectively measured or evaluated as an indicator of normal biological 682	  
processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention  683	  
Chimeric antigen receptor (CAR) T cells: artificial engineered T cell receptors, which graft specificity 684	  
onto an immune effector cell. 685	  
Clonal evolution: the process of acquisition of genomic/epigenomic aberrations in multicellular 686	  
organisms, such as a tumor  687	  
Clonal mutation: Aberration that exists in the vast majority of the tumor cells  688	  
Epigenetic: changes that occur in gene expression if cellular phenotype due to mechanisms other than 689	  
changes in the DNA sequence 690	  
Immunoediting: changes in the immunogenicity of tumors due to the anti-tumor response of the 691	  
immune system, resulting in the emergence of immune-resistant variants. 692	  
Immunogenicity: the ability of a substance to provoke a humoral and/or cell-mediated immune response 693	  
in the body 694	  
Immunotherapy: the prevention or treatment of disease with agents that stimulate the host’s immune 695	  
response. 696	  
Intertumor heterogeneity: (epi)genetic differences between two tumors 697	  
Intratumor heterogeneity: (epi)genetic differences within the same tumor specimen 698	  
Mutagenesis: process by which the genetic information of an organism is changed in a stable manner, 699	  
resulting in a mutation. It may occur spontaneously in nature, or as a result of exposure to mutagens 700	  
Neoantigens: antigens encoded by tumor-specific mutated genes. 701	  
Next generation sequencing: non-Sanger-based high-throughput DNA sequencing technologies. 702	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Nonsynonymous mutation: point mutation in a protein-coding region that alters the amino acid sequence 703	  
of a tumor, including missense, nonsense, splice site and indel mutations. 704	  
‘OMIC technology: informal field of study in biology ending in -omics, such as genomics, proteomics or 705	  
metabolomics. 706	  
Oncogene: gene with the potential to cause cancer 707	  
Organoid: three-dimensional organ-bud grown in vitro with realistic micro-anatomy and comparable 708	  
genomic landscape to parent tissue of origin 709	  
Precision Medicine: "an emerging approach for disease treatment and prevention that takes into 710	  
account individual variability in genes, environment, and lifestyle for each person" [definition 711	  
National Institutes of Health (NIH)]; “a form of medicine that uses information about a person’s 712	  
genes, proteins, and environment to prevent, diagnose, and treat disease” [definition of National 713	  
Cancer Institute (NCI)].  714	  
Selection pressure: The extent to which organisms possessing a particular characteristic are 715	  
either eliminated or favored by environmental demands. 716	  
Subclonal mutation: an aberration that exists in only a subset of the tumor cells 717	  
Theranostic: coined to define ongoing efforts to combine diagnostic and therapeutic capabilities into a 718	  
single agent. 719	  
Tumor suppressor gene: gene that protects a cell from one step on the path to cancer. When mutated, 720	  
can cause a loss or reduction in its function and the cell can progress to cancer, usually in combination 721	  
with other genetic changes. 722	  
Umbrella trial: test the impact of different drugs on different mutations often in a single cancer type.  723	  
Whole Exome Sequencing: a technique for sequencing all the coding genes in a genome (known as the 724	  
exome) 725	  
Whole Genome Sequencing: a laboratory process that determines the complete DNA sequence of an 726	  
organism's genome at a single time. 727	  
